At this time, there are no generic versions of Multaq (dronedarone) licensed for sale. The medication is no longer under the protection of its first patent. However, it is possible that there is a later-expiring patent, or perhaps exclusivity rights, protecting Multaq from generic competition.
Generic Multaq: An Overview
Multaq® (dronedarone) is a prescription drug used to treat irregular heart rhythms (arrhythmias). Specifically, it is used to prevent heart-related hospitalizations in people with atrial fibrillation or atrial flutter. Multaq does not belong to any one particular class of medications (other than the general class of arrhythmia medications).
Most arrhythmia medications are classified using the Vaughn-Williams classification system, which divides arrhythmia medications into four classes depending on how they work. At this point, it seems that Multaq has activity that belongs to all four of the classes.
Multaq is manufactured by Sanofi Winthrop Industries for sanofi-aventis U.S. LLC.
When Will a Generic Version Be Available?
The first patent for Multaq expired in July 2012, yet no generic versions are available yet. This probably means that a later-expiring patent or exclusivity rights (which are similar to patents) are still protecting the drug against generic competition. The exclusivity rights for Multaq (which sometimes, but not always, protect a drug from generic competition) expire in July 2014. This is the earliest predictable date that a generic version of Multaq could become available.
However, there are other circumstances that could come up to extend or shorten the exclusivity period of Multaq. This could include such things as lawsuits or other Multaq patents. Once Multaq goes off patent, there may be several companies that will manufacture a generic Multaq drug.